Idera Pharmaceuticals to Present at BIO InvestorForum
October 18 2005 - 9:05AM
PR Newswire (US)
CAMBRIDGE, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Idera
Pharmaceuticals, Inc. (AMEX:IDP) announced today that Sudhir
Agrawal, D. Phil, Chief Executive Officer and Chief Scientific
Officer of Idera Pharmaceuticals, Inc. will present an overview of
the Company, its product pipeline and its technology to investors
at the BIO InvestorForum, taking place at The Palace Hotel in San
Francisco. The presentation will be made on Thursday, October 20,
2005 at 1:40 p.m. PT in the Telegraph Hill Room. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc. is a
biotechnology company focused on the discovery, development, and
commercialization of targeted immune therapies based on modulation
of Toll-like Receptors (TLRs). Idera has identified novel chemical
entities that modulate immune responses through interactions with
TLR9. The Company continues to identify new drug candidates
specific to various diseases, including cancer, infectious diseases
and asthma/allergies, based on the differentiated biological
activities of its proprietary compounds. The Company's website is
located at http://www.iderapharma.com/. Idera Pharmaceuticals
(AMEX:IDP) is based in Cambridge, Massachusetts. Idera's lead
candidate is IMO2055, a TLR9 agonist currently in Phase 2 clinical
testing for cancer. Idera is also collaborating with Novartis for
the discovery, development, and commercialization of IMO drug
candidates targeting asthma and allergies. Forward Looking
Statements This press release contains forward-looking statements
concerning Idera Pharmaceuticals, Inc. that involve a number of
risks and uncertainties. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed to
be forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance through the clinical trial process
on a timely basis or at all and receive approval from the United
States Food and Drug Administration or equivalent foreign
regulatory agencies; whether, if such products receive approval,
they will be successfully distributed and marketed; whether Idera's
cash resources will be sufficient to fund product development and
clinical trials; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on
Form 10-Q filed on August 9, 2005, which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements. Contacts:
Idera Pharmaceuticals, Inc. MacDougall Biomedical Communications
617-679-5500 x5517 508-647-0209 x12 Robert G. Andersen Douglas
MacDougall E-mail: E-mail: DATASOURCE: Idera Pharmaceuticals, Inc.
CONTACT: Robert G. Andersen of Idera Pharmaceuticals, Inc.,
+1-617-679- 5500 ext 5517, ; or Douglas MacDougall of MacDougall
Biomedical Communications, +1-508-647-0209 ext 12, or Web site:
http://www.iderapharma.com/
Copyright
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024